Slow flow is a serious complication in percutaneous coronary intervention (PCI) and is associated with poor clinical outcomes. Our previous study revealed that the ratio of stent diameter to vessel diameter was the determinant of slow flow in intravascular ultrasound (IVUS)-guided PCI to the culprit lesion of ST elevation myocardial infarction (STEMI). The purpose of this study was to verify whether the ratio of stent diameter to vessel diameter is the determinant of slow flow in IVUS-guided PCI to the culprit lesion of non-STEMI (NSTEMI). We included 150 NSTEMI patients and divided into the slow flow group (n = 17) and the non-slow flow group (n = 133). The ratio of stent diameter to vessel diameter was significantly larger in the slow flow group (0.77 ± 0.11) than the non-slow flow group (0.71 ± 0.11) (P = 0.03). Multivariate logistic regression analysis revealed that the ratio of stent diameter to vessel diameter (per 0.1 increase: OR 2.06, 95% CI 1.23-3.46, P = 0.006) was the determinant of slow flow after controlling covariates. In conclusion, the ratio of stent diameter to vessel diameter was the determinant of slow flow in IVUS-guided PCI to the culprit lesion of NSTEMI. Unlike other parameters, the ratio of stent diameter to vessel diameter is the modifiable parameters. We may consider the modest stent expansion strategy rather than the aggressive stent expansion strategy in IVUS-guided PCI to the culprit lesion of NSTEMI. (Int Heart J 2018; 59: 1237-1245 
I n the treatment of acute myocardial infarction (AMI), slow flow phenomenon is not uncommon and is closely related to worse clinical outcomes. 1, 2) While several studies revealed the determinants of slow flow during percutaneous coronary intervention (PCI), 3, 4) effective methods for preventing slow flow phenomenon have not been established partly because either thrombus aspiration or distal protection devices are not recommended in current guidelines. 5, 6) Furthermore, most of the determinants of slow flow such as aging, initial Thrombolysis In Myocardial Infarction (TIMI) flow grade or low attenuation plaque are not modifiable factors at the timing of primary PCI. Recently, we reported that the ratio of stent diameter to vessel diameter was the determinant of slow flow following stent implantation in ST elevation myocardial infarction (STEMI) patients. 7) Unlike aging, initial TIMI flow, or low attenuation plaque, the ratio of stent diameter to vessel diameter is the modifiable parameter because we can select stent size at the timing of PCI. Therefore, we suggested that the modest stent expansion strategy (the ratio of stent diameter to vessel diameter < 0.71) could be considered to prevent slow flow following stent implantation in IVUS-guided primary PCI for STEMI patients.
On the other hand, recent imaging studies revealed the difference of plaque type between STEMI and non-ST elevation myocardial infarction (NSTEMI). 8, 9) In brief, plaque rupture is the dominant cause of STEMI, while plaque erosion and calcified nodule were more frequently observed in the culprit lesion of NSTEMI than that of STEMI. [8] [9] [10] Therefore, the determinants of slow flow may be different between STEMI and NSTEMI. The purpose of the present study was to verify whether the ratio of stent diameter to vessel diameter can be a modifiable determinant of slow flow in patients with NSTEMI.
Methods

Study patients:
We identified AMI patients from hospital records in our medical center from January 2012 to December 2016. The diagnosis of AMI required the following criteria: symptom consistent with AMI, elevated cardiac enzyme including Troponin T, Troponin I, and/or creatinine kinase (at least 2-folds increase from normal upper limit), and ST-segment changes in electrocardiograms compatible with AMI. 11) Slow flow was defined as flow worsening following stent implantation as compared to the flow before stenting. 7, 12) Slow flow included transient flow worsening following stent implantation as well as persistent flow worsening which was refractory to any procedures such as intra coronary injection of nitroprusside. 7) When flow worsening was not clear, TIMI frame count was used to judge slow flow. 13) The inclusion criteria were (1) NSTEMI, (2) stent implantation was undergone to the infarct related artery of NSTEMI, and (3) IVUS was used before stent implantation. The exclusion criteria were (1) use of venous-arterial extracorporeal membrane oxygenation, (2) NSTEMI caused by coronary spastic angina, (3) NSTEMI caused by spontaneous coronary artery dissection, (4) NSTEMI caused by in-stent failure, (5) use of distal protection devices, and (6) coronary artery bypass grafting to the infarct related artery of NSTEMI. We divided our study population into the patients who had slow flow (slow flow group) and the patients who did not have slow flow (nonslow flow group). Clinical characteristics were compared between the slow flow and non-slow flow groups. Inhospital and mid-term clinical outcomes were also acquired from hospital records. This study was approved by the institutional review board and written informed consent was waived because of the retrospective study design. Definition: Hypertension was defined as medical treatment for hypertension and/or a history of hypertension before admission. 14) Dyslipidemia was defined as total cholesterol level !220 mg/dL or low-density lipoprotein cholesterol level ! 140 mg/dL or medical treatment for dyslipidemia or a history of dyslipidemia. 14) Diabetes mellitus was defined as hemoglobin A1c level !6.5% (as NGSP value) or medical treatment for diabetes mellitus or a history of diabetes mellitus. 14) We also calculated estimated glomerular filtration rate (eGFR) from the serum creatinine level, age, weight, and gender using the following formula; eGFR = 194 × Cr −1.094 × age −0.287 (male), eGFR = 194 × Cr −1.094 × age −0.287 × 0.739 (female). 15) Impaired renal function was defined as eGFR < 60 mL/minute/1.73 m 2 . 16) Shock status was defined as systolic blood pressure < 90 mmHg or vasopressors required to maintain blood pressure or an attempt of cardiopulmonary resuscitation. 14) Significant coronary artery stenosis was defined as at least a 75% reduction in the internal diameter of the right, left anterior descending or left circumflex coronary arteries (LCx) or their major branch, or a 50% reduction in the internal diameter of the left main trunk. Thrombus on angiography was defined as TIMI thrombus grade ! 2. 3) TIMI frame count in the IRA was calculated as the number of cineframes needed for contrast to reach standardized distal coronary landmark. 13) Myocardial blush grade was defined as follows: 0, no myocardial blush or contrast density; 1, minimal myocardial blush or contrast density; 2, moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary artery; and 3, normal myocardial blush or contrast density, comparable with that obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary artery. 17) Myocardial brush grade was measured by an experienced cardiologist (YW) under the supervision of the senior cardiologist (KS). Chronic total occlusion was defined as a 100% luminal narrowing in a non-IRA before PCI without ante-grade flow and with antegrade or retrograde filling by collateral vessel. 18) A major adverse cardiac event (MACE) was defined as the composite of all cause death, no fatal myocardial infarction, and ischemic-driven target vessel revascularization (TVR) within 1 year from PCI to the culprit lesion of NSTEMI. 19, 20) From coronary angiogram, the reference diameter, lesion length, stenosis rate, and minimum diameter were calculated by quantitative coronary angiographic analysis (QCA). Offline, computerbased software QAngio XA 7.3 (MEDIS Imaging Systems, Leiden, Netherlands) was used for QCA. The lesion diameter, external elastic membrane area, lumen area, and plaque area at lesion were acquired from IVUS analysis. Qualitative and quantitative analysis of grayscale IVUS images were performed according to the criteria of the American College of Cardiology's Clinical Expert Consensus Document on IVUS. 21) Ratio of stent diameter to vessel diameter was calculated in each lesion, using actual vessel diameter measured in IVUS before stent implantation and prespecified stent diameter (nominal pressure). 7) Statistical analysis: Data are expressed as mean ± S.D. or percentage. Categorical variables are presented as numbers (percentage) and compared with Pearson's χ 2 test or Fisher's exact test. The Kolmogorov-Smirnov test was performed to determine if the continuous variables were normally distributed. Normally distributed continuous variables were compared between the groups using an unpaired Student t test. Otherwise, continuous variables were compared using a Mann-Whitney U test. Multivariate logistic regression analysis was performed to investigate whether determinants of slow flow in STEMI are determinants of slow flow in NSTEMI. Multivariate logistic regression model used variables that were the determinants of slow flow in patients with STEMI in our previous study. 7) The selected variables were age (per 1-year-old), ratio of stent diameter to vessel diameter (per 0.1 increase), thrombus on angiography (TIMI thrombus grade !2), initial TIMI flow grade (versus TIMI 0 flow), and low attenuation plaque on IVUS. 7) The odds ratio (OR) and the 95% confidence interval (CI) were calculated. A P value < 0.05 was considered statistically significant. 22) Moreover, we divided study patients into an aggressive stent expansion group (ratio of stent diameter to vessel diameter !0.71) and a modest stent expansion group (ratio of stent diameter to vessel diameter < 0.71) by using a cut-off value of 0.71, which was used in the previous study. 7) We compared cumulative survival free of ischemic-driven TVR within 1 year between the groups. The log-rank test was used to compare long-term clinical events. All analyses were performed using statistical software, SPSS 23.0/Windows (SPSS, Chicago, IL).
Results
Among 979 AMI patients admitted to our hospital from January 2012 to December 2016, a total of 150 cases (17 in the slow flow group and 133 in the non-slow flow group) were included as the final study population ( Figure 1) . Table I shows a comparison of patient characteristics between the two groups. Clinical characteristics were comparable between the two groups except history DETERMINANTS OF SLOW FLOW IN NSTEMI of cerebrovascular disease and peripheral artery disease. Table II shows comparisons of lesion characteristics and IVUS findings between the groups. The incidence of thrombus on angiography (TIMI thrombus grade ! 2) was significantly greater in the slow flow group (29.4%) than in the non-slow flow group (7.5%) (P = 0.02). The ratio of stent diameter to vessel diameter was also significantly larger in the slow flow group (0.77 ± 0.11) than in the non-slow flow group (0.71 ± 0.11) (P = 0.03). Table III shows comparisons of clinical outcomes between the groups. Myocardial blush grade was significantly less in the slow flow group (2.35 ± 0.70) than in the non-slow flow group (2.74 ± 0.51) (P = 0.01). Composite MACE within 1 year was not significantly different between the two groups.
In Table IV , multivariate logistic regression analysis was performed to investigate whether the ratio of stent diameter to vessel diameter can be a modifiable determinant of slow flow in patients with NSTEMI. The ratio of stent diameter to vessel diameter (per 0.1 increase, OR 2.06, 95% CI 1.23-3.46, P = 0.006) was significantly associated with slow flow even after controlling other confounding factors. Thrombus on angiography was also significantly associated with slow flow, whereas age, initial TIMI flow grade, and low attenuation plaque were not significantly associated with slow flow.
Then, we divided study patients into an aggressive stent expansion group (ratio of stent diameter to vessel diameter !0.71) and a modest stent expansion group (ratio of stent diameter to vessel diameter < 0.71). The mean stent diameter of the aggressive stent expansion and modest stent expansion groups were 3.08 ± 0.53 mm and 2.84 ± 0.45 mm, respectively (P = 0.004). The incidence of slow flow phenomenon was significantly higher in the aggressive stent expansion group (16.9%) compared with that in the modest stent expansion group (6.3%) (P = 0.04). We compared cumulative survival free of ischemicdriven TVR within 1 year between the aggressive stent expansion and the modest stent expansion groups, and there was no significant difference between the groups (Figure 2 ).
Discussion
This study aimed to verify whether the ratio of stent diameter to vessel diameter can be a modifiable determinant of slow flow in patients with NSTEMI. We evaluated 150 NSTEMI patients treated by IVUS-guided stent implantation and found that 17 patients (11.3%) had slow flow following stent implantation during PCI. Multivariate logistic regression analysis revealed that the ratio of stent diameter to vessel diameter was the significant determinant of slow flow following stent implantation in patients with NSTEMI. Unlike other variables, the ratio of stent diameter to vessel diameter is the modifiable variable in IVUS-guided PCI to the culprit lesion of NSTEMI. Although IVUS-guided PCI has shown an advantage of larger stents for better long-term outcomes, 23) our results may support the modest stent expansion strategy for the prevention of slow flow in patients with NSTEMI as well as patients with STEMI. 7) Although there are significant differences in presentation, angiographic findings and treatment strategy between STEMI and NSTEMI, [24] [25] [26] slow flow phenomenon is associated with worse clinical outcomes in both STEMI and NSTEMI. Thus, it is important to prevent slow flow in PCI to the culprit lesion of NSTEMI. 24) However, clinical studies regarding thrombus aspiration in NSTEMI could not show clinical benefits, 27, 28) while thrombus aspiration might decrease atherothrombotic burden. 29) Therefore, there have been no established strategies to reduce slow flow in PCI to the culprit lesion of NSTEMI.
We should explain the modest stent expansion strategy. Although we used a cut-off value < 0.71 as the ratio of stent diameter to vessel diameter, this 0.71 was just derived from our previous study population, 7) which may not be applicable to other populations. The main point of the modest stent expansion strategy was to avoid stent overexpansion. Because the culprit of acute coronary syndrome shows greater positive remodeling than that of stable disease, 30) operators tend to select big stent if only the positively remodeled culprit was used for vessel reference. In the modest stent expansion strategy, we might select appropriate size of stent by checking the lumen size at the distal reference segments 31) rather than the lumen size at the culprit. Therefore, the modest stent expansion strategy Watanabe, ET AL was not equal to the underexpansion strategy. If there was a focal underexpansion (indentation in the stent), we would not hesitate to add post-balloon dilatation. The modest stent expansion strategy is the simple strategy, which does not require additional devices except IVUS in PCI. Because the culprit lesion of acute coronary syndrome is composed of fragile tissue such as lipid deposition with foam cells, cholesterol crystals, microcalcification, and thrombus, 32) the mechanism of reducing slow flow in the modest stent expansion strategy is that the smaller diameter stent would extrude less fragile tissue from culprit lesions in NSTEMI. The larger diameter stent would be necessary to have long-term patency 23) but may not have TIMI-3 flow in the acute phase. The main concern of the modest stent expansion strategy is the late stent failure including stent thrombosis and restenosis caused by underexpansion. 33, 34) Although incidences of ischemic-driven TVR within 1 year were not different between the modest stent expansion and the aggressive stent expansion groups in the present study, longer follow-up data would be needed to confirm the safety of the modest expansion strategy. Although the significant association between slow flow and worse clinical outcomes has been reported, 1,2) the composite MACE was not different between the slow flow and the non-slow flow groups. Only myocardial brush grade, which is a surrogate marker of clinical outcomes, was significantly worse in the slow flow group than in the non-slow flow group. One of the reasons why MACEs were not different between the two groups may be the relatively low incidence of MACEs (approximately 10%) in the present study. For example, Dong-bao, et al. reported that MACE within 6 months was observed in 17% of STEMI patients with slow/no-reflow. 2) Furthermore, our previous study also reported that MACE was observed in 18% of STEMI patients with slow flow. 7) Because the incidence of short-term MACE is generally lower in NSTEMI than in STEMI, 10, 35, 36) larger number of study pa-tients and longer follow-up duration would be needed to detect the differences in MACE between the slow flow and the non-slow flow groups in NSTEMI. Study limitation: Since this study was a single-center retrospective observational study, there is a risk of selection bias. Because the cut-off value 0.71 of the ratio of stent diameter to vessel diameter was derived from our previous study, 7) the cut-off value 0.71 may not be optimal for all NSTEMI patients. Although the ratio of stent diameter to vessel diameter was significantly associated with slow flow, the incidence of MACE was not different between the slow flow and non-slow flow group. We excluded DETERMINANTS OF SLOW FLOW IN NSTEMI Figure 2 . Kaplan-Meier curves of cumulative survival free of ischemic-driven TVR events. Survival curves are shown for both the aggressive stent expansion and modest stent expansion groups. A log-rank test showed no significant difference between the two groups (P = 0.09). NSTEMI patients whose culprit lesion was an in-stent lesion, because it was difficult to accurately measure the ratio of stent diameter to vessel diameter. Furthermore, this study was underpowered to prove the safety of modest stent expansion. In addition, although the low attenuation plaque was considered as a risk factor for slow flow phenomenon and distal embolization, 30) our study could not show the significant association between the low attenuation plaque and slow flow, while the presence of low attenuation plaque was numerically greater in the slow flow group (52.9%) than in the non-slow flow group (36.1%) without reaching statistical significance (P = 0.18). This study was also underpowered to prove the association between the low attenuation plaque and slow flow. Finally, the present study was observational in nature, and our findings need to be confirmed prospectively in a randomized controlled trial.
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Conclusions
The ratio of stent diameter to vessel diameter was the determinant of slow flow following stent implantation in IVUS-guided PCI to the culprit lesion of NSTEMI. The advantage of a modest stent expansion strategy should be considered to prevent slow flow following stent implantation in IVUS-guided PCI in NSTEMI.
